Working… Menu

A Study to Assess the Safety, Tolerability, Effectiveness and Absorption of Exodif™ Tablets in Clostridium Difficile-associated Diarrhea

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00466635
Recruitment Status : Terminated
First Posted : April 27, 2007
Last Update Posted : March 19, 2015
Information provided by:

Brief Summary:
Approximately 65 patients will be entered into this study taking place in North America. The aim of this study is to evaluate the safety, efficacy and absorption of an investigational drug in patients with C. difficile-associated diarrhea (CDAD). All study related care is provided including doctor visits, physical exams, laboratory tests and study medication. Total length of participation is 6 weeks.

Condition or disease Intervention/treatment Phase
Enterocolitis, Pseudomembranous Diarrhea Clostridium Difficile Drug: GT267-004 (tolevamer potassium sodium) Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 65 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label Study to Assess the Safety, Efficacy and Absorption of Exodif™ (Tolevamer Potassium Sodium) Tablets in Patients With Clostridium Difficile-Associated Diarrhea
Study Start Date : April 2007
Actual Study Completion Date : August 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diarrhea Potassium

Primary Outcome Measures :
  1. Clinical Success
  2. Safety

Secondary Outcome Measures :
  1. The extent of tolevamer absorption

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The presence of CDAD at the time of enrollment
  • Negative serum pregnancy test (HCG) for women of childbearing potential.

Exclusion Criteria:

  • Any contraindication to oral / enteral therapy including fulminant C. difficile disease.
  • Any acutely life-threatening medical conditions.
  • Acute or chronic diarrhea of other cause.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00466635

Layout table for location information
United States, California
Modesto, California, United States
United States, Hawaii
Honolulu, Hawaii, United States
United States, Illinois
Maywood, Illinois, United States
United States, Maryland
Baltimore, Maryland, United States
United States, Massachusetts
Worcester, Massachusetts, United States
United States, Michigan
West Bloomfield, Michigan, United States
United States, Montana
Butte, Montana, United States
United States, New Jersey
Cedar Knolls, New Jersey, United States
Neptune, New Jersey, United States
United States, New York
Syracuse, New York, United States
United States, North Carolina
Greenville, North Carolina, United States
United States, Ohio
Toledo, Ohio, United States
United States, Pennsylvania
Lancaster, Pennsylvania, United States
Sponsors and Collaborators
Genzyme, a Sanofi Company
Layout table for investigator information
Study Director: Medical Monitor Genzyme, a Sanofi Company

Layout table for additonal information
Responsible Party: Medical Monitor, Genzyme Corporation Identifier: NCT00466635     History of Changes
Other Study ID Numbers: TOL26700706
First Posted: April 27, 2007    Key Record Dates
Last Update Posted: March 19, 2015
Last Verified: March 2015
Keywords provided by Sanofi:
Clostridium difficile Disease
Infectious diarrhea
C. difficile
Clostridium difficile-associated diarrhea
Clostridium difficile diarrhea
Antibiotic-Associated Colitis
Clostridium Enterocolitis
Antibiotic-Associated Diarrhea
Pseudomembranous Colitis
Clostridium difficile
Additional relevant MeSH terms:
Layout table for MeSH terms
Clostridium Infections
Enterocolitis, Pseudomembranous
Signs and Symptoms, Digestive
Signs and Symptoms
Gram-Positive Bacterial Infections
Bacterial Infections
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
Anti-Bacterial Agents
Anti-Infective Agents